What Your AA:EPA Ratio Is Telling You About Systemic Inflammation

← Back to Clinical Articles

Article: What Your AA:EPA Ratio Is Telling You About Systemic Inflammation  |  Category: Inflammation  |  Authored by: Brian Lamkin, DO

The Cell Membrane Is the Battlefield

Every cell in the body has a phospholipid membrane, and the fatty acid composition of that membrane determines the cell's inflammatory potential. When a cell is activated (by injury, infection, or immune signaling), enzymes (phospholipase A2, cyclooxygenase, lipoxygenase) cleave fatty acids from the membrane and convert them to eicosanoids, the signaling molecules that control inflammation, pain, clotting, and immune activation^[1]. If the membrane is rich in arachidonic acid (AA, an omega-6 fatty acid), the eicosanoids produced are pro-inflammatory: prostaglandin E2 (pain, swelling, vasodilation), thromboxane A2 (platelet aggregation, vasoconstriction), and leukotriene B4 (neutrophil recruitment, tissue damage). If the membrane is rich in eicosapentaenoic acid (EPA, an omega-3 fatty acid), the eicosanoids produced are anti-inflammatory: prostaglandin E3, thromboxane A3, and leukotriene B5, all of which are significantly less inflammatory than their AA-derived counterparts. The AA:EPA ratio is therefore a direct measure of the inflammatory potential built into every cell membrane in the body.

Why the Standard American Diet Produces a Dangerous Ratio

The human evolutionary diet had an omega-6:omega-3 ratio of approximately 1:1 to 2:1^[2]. The modern Western diet, dominated by seed oils (soybean, corn, canola, sunflower, safflower), fried foods, and processed foods, produces a ratio of 15:1 to 25:1. This means the average American's cell membranes contain 15 to 25 times more pro-inflammatory substrate than anti-inflammatory substrate. Every time a cell is activated, the inflammatory response is disproportionately skewed toward tissue-damaging, pain-producing, clot-promoting eicosanoids. This is not a theoretical risk. It is a measurable, cellular-level inflammatory state that persists regardless of whether the patient "feels inflamed" or whether their hs-CRP is normal. The AA:EPA ratio catches inflammatory potential that hs-CRP misses.

Beyond hs-CRP: What the AA:EPA Ratio Reveals That Standard Markers Do Not

hs-CRP is an acute-phase protein produced by the liver in response to IL-6 signaling. It reflects current systemic inflammatory activity and is the standard inflammatory marker in conventional medicine. However, hs-CRP has significant limitations: it can be normal in patients with tissue-level inflammation that has not yet activated the hepatic acute-phase response, it fluctuates with transient events (acute illness, vigorous exercise, minor infections), and it does not identify the source or substrate of inflammation. The AA:EPA ratio is fundamentally different. It measures the fatty acid composition of red blood cell membranes, which reflects the previous 90 to 120 days of fatty acid intake and metabolism. It represents the chronic, cellular-level inflammatory potential rather than the current acute-phase response. A patient can have normal hs-CRP and a severely elevated AA:EPA ratio, meaning their cells are primed for inflammatory eicosanoid production even in the absence of current measurable inflammation. This patient is at elevated risk for cardiovascular events, autoimmune flares, and neuroinflammation even though their "inflammation labs are normal."

Specialized Pro-Resolving Mediators: Why EPA Matters Beyond Reducing Inflammation

EPA does not merely produce "less inflammatory" eicosanoids. It is also the precursor for specialized pro-resolving mediators (SPMs): resolvins, protectins, and maresins^[3]. These molecules actively resolve inflammation rather than merely suppressing it. They signal macrophages to clear inflammatory debris, promote tissue repair, and return the immune system to baseline. This is mechanistically different from anti-inflammatory drugs (NSAIDs, corticosteroids) that block the inflammatory response without promoting resolution. In patients with chronic inflammation, resolution pathways are often impaired because EPA substrate is insufficient to produce adequate SPMs. The AA:EPA ratio identifies this resolution failure: a high ratio means not only excess pro-inflammatory eicosanoid production but also insufficient resolution capacity.

Cardiovascular Risk and the AA:EPA Ratio

The relationship between the AA:EPA ratio and cardiovascular risk is well documented. AA-derived thromboxane A2 promotes platelet aggregation and vasoconstriction. EPA-derived thromboxane A3 is significantly less pro-aggregatory. AA-derived prostaglandin E2 promotes vascular inflammation and endothelial dysfunction. EPA-derived prostaglandin E3 has minimal vascular inflammatory effect. A high AA:EPA ratio therefore promotes the pro-thrombotic, pro-inflammatory vascular environment that drives atherosclerosis, endothelial dysfunction, and cardiovascular events. This is independent of and additive to traditional cardiovascular risk factors (LDL, blood pressure, smoking). Evaluating the AA:EPA ratio alongside triglyceride:HDL ratio, hs-CRP, oxidized LDL, and Lp-PLA2 provides a comprehensive assessment of cardiovascular inflammatory risk that standard lipid panels cannot match.

Autoimmune Disease and Fatty Acid Balance

Autoimmune disease is driven by immune activation and impaired immune tolerance. The AA:EPA ratio directly influences both. AA-derived leukotriene B4 is a potent activator of neutrophils and Th1 immune responses. EPA-derived leukotriene B5 is 10 to 100 times less potent. AA-derived prostaglandin E2 promotes Th17 differentiation (the inflammatory T-cell subset most implicated in autoimmune tissue destruction). EPA-derived resolvins promote regulatory T-cell function (the tolerance-promoting T-cell subset). A high AA:EPA ratio in an autoimmune patient means the cellular environment is tilted toward immune activation and away from tolerance at the eicosanoid level. Optimizing the ratio does not cure autoimmunity, but it shifts the tissue-level immune environment from one that promotes flares to one that promotes resolution. This is why omega-3 supplementation at adequate doses (3 to 4g EPA/DHA daily) is a cornerstone of functional medicine autoimmune management.

Neuroinflammation and Brain Health

The brain is approximately 60 percent fat by dry weight, and neuronal cell membranes are particularly enriched in long-chain polyunsaturated fatty acids. DHA (docosahexaenoic acid, the other major omega-3) is the predominant structural fatty acid in brain membranes, while EPA plays the primary anti-inflammatory role. A high AA:EPA ratio in the systemic circulation reflects the fatty acid environment available to the brain. Microglial cells (the brain's immune cells) produce eicosanoids from membrane fatty acids just as peripheral immune cells do. When AA predominates, microglial activation produces neuroinflammatory eicosanoids that impair synaptic function, reduce neuroplasticity, and contribute to the brain fog, cognitive decline, and mood disruption seen in chronic inflammatory conditions. Optimizing the AA:EPA ratio reduces the substrate available for neuroinflammatory eicosanoid production and increases the substrate for neuroprotective SPMs.

Insulin Resistance and Metabolic Inflammation

The connection between fatty acid balance and insulin resistance operates at the cell membrane level. Cell membranes with high AA content and low EPA content are more rigid, less fluid, and less responsive to insulin receptor signaling^[4]. Additionally, AA-derived prostaglandin E2 directly impairs insulin signaling in adipose tissue and skeletal muscle. Patients with elevated fasting insulin and a high AA:EPA ratio have two concurrent drivers of metabolic dysfunction: the insulin resistance itself and the membrane-level inflammatory environment that compounds it. Optimizing the fatty acid ratio improves membrane fluidity and insulin receptor function, producing measurable improvement in HOMA-IR that is additive to dietary and exercise interventions.

Testing: How to Measure the AA:EPA Ratio

The AA:EPA ratio is measured through a blood fatty acid analysis. The most commonly used test is the OmegaQuant Omega-3 Index, which measures red blood cell membrane fatty acid composition and reports both the Omega-3 Index (EPA + DHA as a percentage of total red blood cell fatty acids, target above 8 percent) and the AA:EPA ratio. Alternative options include the LabCorp or Quest fatty acid profile and specialty functional medicine panels. The test uses either a dried blood spot (finger stick) or a standard blood draw. No fasting is required. Because the test measures red blood cell membrane composition, it reflects the previous 90 to 120 days of fatty acid intake and metabolism, making it resistant to day-to-day fluctuations. Retest at 3 months after initiating or adjusting omega-3 supplementation to confirm response.

How to Modify the Ratio

The AA:EPA ratio is one of the most directly modifiable inflammatory markers. The intervention is straightforward: increase EPA intake while reducing AA substrate. Omega-3 supplementation: 2 to 4g combined EPA/DHA daily. For inflammatory conditions (autoimmune, cardiovascular, chronic pain), EPA-dominant formulations (2:1 or 3:1 EPA:DHA) are preferred because EPA is the primary anti-inflammatory eicosanoid precursor. Pharmaceutical-grade fish oil, algae-derived omega-3 (for vegetarians), or prescription omega-3 (Vascepa, icosapent ethyl) are all effective. Quality matters: third-party tested products with IFOS or USP certification ensure purity and accurate EPA/DHA content. Omega-6 reduction: minimize seed oils (soybean, corn, canola, sunflower, safflower), fried foods, and processed foods. Replace with olive oil, avocado oil, and coconut oil. The dietary change reduces the AA substrate being incorporated into cell membranes while the supplementation increases EPA incorporation. Most patients see measurable ratio improvement (from 10:1 or higher to below 5:1) within 8 to 12 weeks of consistent supplementation. Reaching the optimal target of below 3:1 may require 3 to 6 months at adequate doses.

Dose Matters: Why Standard Doses Are Insufficient

Standard over-the-counter fish oil supplements typically contain 300 to 500mg combined EPA/DHA per capsule. At 1 to 2 capsules daily (the dose most commonly recommended by conventional physicians), the total EPA/DHA intake is 300 to 1000mg. This dose is insufficient to meaningfully shift the AA:EPA ratio in most patients. Published evidence supporting cardiovascular, anti-inflammatory, and metabolic benefit uses doses of 2 to 4g combined EPA/DHA daily. In patients with significantly elevated ratios (above 10:1) or active inflammatory conditions, doses of 3 to 4g may be needed for the first 3 months to load cell membranes with EPA before reducing to a maintenance dose of 2 to 3g. The dose should be guided by follow-up AA:EPA testing, not by arbitrary standard recommendations.

The Lamkin Clinic Approach

The AA:EPA ratio is included in the comprehensive inflammatory assessment at The Lamkin Clinic alongside hs-CRP, fasting insulin, triglyceride:HDL ratio, and vitamin D. Together these markers provide a multi-dimensional assessment of inflammation that spans acute-phase response (hs-CRP), cellular membrane potential (AA:EPA), metabolic inflammation (fasting insulin), immune regulation capacity (vitamin D), and cardiovascular risk (triglyceride:HDL). Omega-3 supplementation is dosed based on the baseline ratio, the clinical context (autoimmune, cardiovascular, metabolic, or neuroinflammatory), and follow-up testing at 3 months. The goal is not simply supplementing omega-3 at a generic dose. The goal is measuring the cellular inflammatory environment, intervening at a therapeutic dose, and confirming the response with repeat testing.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56(8):365-379.
2. [2]Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505.
3. [3]Serhan CN, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21(2):325-332.
4. [4]Asher A, et al. Blood omega-3 fatty acids and death from COVID-19: a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2021;166:102250.